Whitehawk Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $7.1M | $26.0M | $24.4M | $15.2M | $14.0M |
| Cost of revenue | $760,000 | $3.0M | $2.8M | $1.3M | $0 |
| Selling, general & administrative | $29.8M | $36.7M | $44.5M | $40.2M | $18.5M |
| Research and development | $91.0M | $51.0M | $48.9M | $32.7M | $19.7M |
| Operating expenses | — | — | — | — | $112.3M |
| Operating income | -$114.4M | -$67.5M | -$71.9M | -$62.7M | -$111.2M |
| Interest expense | $0 | $154,000 | $231,000 | $230,000 | $665,000 |
| Pretax income | -$20.6M | -$63.7M | -$65.8M | -$60.5M | -$110.1M |
| Income tax expense | $0 | $0 | $0 | $0 | $2,000 |
| Net income | -$20.6M | -$63.7M | -$65.8M | -$60.5M | -$110.1M |
| Balance Sheet | |||||
| Cash and equivalents | $37.6M | $28.7M | $62.9M | $39.0M | $149.0M |
| Current assets | $149.0M | $61.3M | $124.6M | $180.0M | $151.3M |
| Total assets | $150.8M | $70.3M | $132.4M | $184.2M | $157.9M |
| Current liabilities | $14.5M | $17.1M | $26.4M | $18.8M | $15.3M |
| Total liabilities | $14.5M | $17.8M | $27.2M | $25.9M | $21.5M |
| Stockholders' equity | $136.3M | $52.5M | $105.2M | $158.4M | $136.4M |
| Cash Flow Statement | |||||
| Cash from operations | -$97.4M | -$59.5M | -$59.7M | -$49.6M | -$22.4M |
| Depreciation and amortization | $79,000 | $193,000 | $169,000 | $159,000 | $105,000 |
| Stock-based compensation | $9.9M | $10.8M | $12.0M | $9.6M | $2.1M |
| Capital expenditure | $552,000 | $1.7M | $4.0M | $444,000 | $46,000 |
| Free cash flow | -$98.0M | -$61.2M | -$63.6M | -$50.1M | -$22.5M |
| Dividends paid | — | — | — | $0 | $4.4M |
| Impairments | — | — | $0 | $3.7M | $74.2M |
Shares outstanding 49.5M · Free float 38.9%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.